Table 1 Anti-malarial drugs collected
Collected and analyzed with TLC (%) | Samples included in disintegration test (% of TLC tested) | Expired before analysis | TLC failures | Disinteg-ration test failures | Average costs (USD) | |
|---|---|---|---|---|---|---|
ACT | ||||||
Artemether-lumefantrine | 177 (41%) | 102 (58%) | 3 | 1 | 0 | 7.6 |
Artesunate-amodiaquine | 42 (10%) | 22 (52%) | 6 | 0 | 0 | 7.2 |
Artesunate-SP | 36 (8%) | 26 (72%) | 1 | 0 | 0 | 8.5 |
Dihydroartemisinin-piperaquine | 38 (9%) | 33 (86%) | 1 | 0 | 0 | 9.9 |
Artesunate-mefloquine | 22 (5%) | 5 (23%) | 1 | 0 | 0 | 9.7 |
Dihydroartemisinin-piperaquine- trimethoprim | 13 (3%) | 12 (92%) | 0 | 0 | 0 | 9.3 |
Dihydroartemisinin-SP | 7 (2%) | 0 (0%) | 0 | 0 | 0 | 4.5 |
Artemisinin-piperaquine | 2 (<1%) | 0 (0%) | 0 | 0 | 0 | 10.1 |
Artemisinin-naphtoquine | 1 (<1%) | 0 (0%) | 0 | 0 | 0 | NR |
Other | ||||||
Quinine | 43 (10%) | 34 (79%) | 0 | 1 | 0 | 9.6 |
Sulphadoxine-pyrimethamine | 40 (9%) | 26 (65%) | 0 | 0 | 1 | 2.2 |
Mefloquine | 4 (<1%) | 2 (50%) | 0 | 0 | 0 | 33.3 |
Atovaquone-proguanil | 2 (<1%) | 0 (0%) | 0 | 0 | 0 | 24.2 |
Proguanil | 2 (<1%) | 0 (0%) | 0 | 0 | 0 | 16.5 |
Proguanil-chloroquine | 2 (<1%) | 0 (0%) | 1 | 0 | 0 | 25.2 |
Pyrimethamine | 1 (<1%) | 0 (0%) | 0 | 0 | 0 | NR |
Total | 432 (100%) | 266 (62%) | 13 (3%) | 2 | 1 | 8.1 |